BiotechTube

Dinutuximab + Vorinostat + Sargramostim + Potassium Iodide

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroblastoma

Conditions

Neuroblastoma

Trial Timeline

Sep 12, 2018 → Feb 23, 2024

NCT ID
NCT03332667

About Dinutuximab + Vorinostat + Sargramostim + Potassium Iodide

Dinutuximab + Vorinostat + Sargramostim + Potassium Iodide is a phase 1 stage product being developed by United Therapeutics for Neuroblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03332667. Target conditions include Neuroblastoma.

What happened to similar drugs?

0 of 1 similar drugs in Neuroblastoma were approved

Approved (0) Terminated (0) Active (1)
🔄18F-MFBGIlluminaPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03332667Phase 1Completed

Competing Products

20 competing products in Neuroblastoma

See all competitors
ProductCompanyStageHype Score
LY3295668 Erbumine + Topotecan + CyclophosphamideEli LillyPhase 1
33
ZD6474 + Retinoic AcidAstraZenecaPhase 1
21
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acidAstraZenecaPhase 2
35
PRRT with 177Lu-DOTATATENovartisPhase 1
36
Topotecan + Temozolomide + RibociclibNovartisPhase 1
21
Topotecan hydrochlorideNovartisPhase 2
35
Ribociclib + CeritinibNovartisPhase 1
21
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + CyclophosphamideRochePhase 2
39
GPC2 CAR T cellsGilead SciencesPhase 1
36
lorlatinibPfizerPre-clinical
18
Lorlatinib + Cyclophosphamide + Topotecan + Filgrastim/pegfilgrastimPfizerPhase 1
29
Nifurtimox + Cyclophosphamide + TopotecanBayerPhase 2
32
DinutuximabUnited TherapeuticsPre-clinical
15
Dinutuximab with ChemotherapyUnited TherapeuticsPhase 1
30
ch14.18 -NCI + ch14.18-UTC + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) + Aldesleukin (IL-2) + IsotretinoinUnited TherapeuticsPhase 1/2
29
Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + TemsirolimusUnited TherapeuticsPhase 2
32
Dinutuximab + NK Cells + LenalidomideUnited TherapeuticsPhase 1
30
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic AcidUnited TherapeuticsPhase 2
24
Radiation: 131I-MIBG + Dinutuximab + VorinostatUnited TherapeuticsPhase 2
39
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSFUnited TherapeuticsPhase 2
39